Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.50 |
| ▸ | IDH1 | O75874 | 9/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | IL6ST | P40189 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8079774 | 0.89 | NAAA (0.51) | NAAAIDH1FAAHALDH1A1PPARA | |
| SCHEMBL7346791 | 0.89 | NAAA (0.47) | NAAAIDH1FAAHALDH1A1PPARA | |
| SCHEMBL1915646 | 0.89 | NAAA (0.47) | NAAAIDH1FAAHALDH1A1PPARA | |
| SCHEMBL1915643 | 0.89 | NAAA (0.47) | NAAAIDH1FAAHALDH1A1PPARA | |
| SCHEMBL24049987 | 0.87 | NAAA (0.46) | NAAAIDH1FAAHPPARAHDAC1 | |
| SCHEMBL20215398 | 0.87 | NAAA (0.46) | NAAAIDH1FAAHPPARAHDAC1 | |
| SCHEMBL21010858 | 0.87 | NAAA (0.46) | NAAAIDH1FAAHPPARAHDAC1 | |
| SCHEMBL2888230 | 0.87 | NAAA (0.46) | NAAAIDH1FAAHPPARAHDAC1 | |
| SCHEMBL9758542 | 0.87 | NAAA (0.46) | NAAAIDH1FAAHPPARAHDAC1 | |
| SCHEMBL18833072 | 0.87 | NAAA (0.46) | NAAAIDH1FAAHPPARAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175587-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN KETTERING INST CANCER (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140213618-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN KETTERING INST CANCER (US) | 2014-07-31 | — | — | US | disclosed |
| US-8513429-B2 | Synthesis of epothilones, intermediates thereto and analogues thereof | SLOAN-KETTERING INSITUTE FOR CANCER RESEARCH (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120316348-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2012-12-13 | — | — | US | disclosed |
| US-8110590-B2 | Synthesis of epothilones, intermediates thereto and analogues thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-02-07 | — | — | US | disclosed |
| US-7875638-B2 | desoxyepothilone A and B; Fludelone; anticarcinogenic agents; drug resistance; water solubility for formulability; industrial scale; cytotoxic or growth inhibitory effects on CAG myeloma cells lines; ability to polymerize tubulin; minimum toxicity; isomerization of the double bonds in the ring | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100197746-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2010-08-05 | — | — | US | disclosed |
| US-7759374-B2 | 12,13-desoxyepothilones, used as anticarcinogenic agents | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-07-20 | — | — | US | disclosed |
| EP-2186811-A1 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | Sloan-Kettering Institute For Cancer Research (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7649006-B2 | Administering epothilones or desoxyepothilones to a cancer patient as anticarcinogenic agent | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-01-19 | — | — | US | disclosed |
| US-7384964-B2 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1767535-A1 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | Sloan-Kettering Institute For Cancer Research (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070032534-A1 | 12,13-desoxyepothilones, used as anticarcinogenic agents | DANISHEFSKY SAMUEL J | 2007-02-08 | — | — | US | disclosed |
| EP-1506203-B1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO, ANALOGUES AND USES THEREOF | SLOAN KETTERING INST CANCER (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1722791-A2 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO, ANALOGUES AND USES THEREOF | Sloan Kettering Institute For Cancer Research (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005084222-A2 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO, ANALOGUES AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050143429-A1 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2005-06-30 | — | — | US | disclosed |
| EP-1506203-A2 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO, ANALOGUES AND USES THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040053910-A1 | Administering epothilones or desoxyepothilones to a cancer patient as anticarcinogenic agent | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-03-18 | — | — | US | disclosed |
| WO-2004018478-A2 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO, ANALOGUES AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316348-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | DHPS, THPO, CYP11B1 | NAAA 4749/4885IDH1 320/4885FAAH 3848/4885 |
| US-20100197746-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | DHPS, THPO, CYP11B1 | NAAA 4749/4885IDH1 320/4885FAAH 3848/4885 |
| US-20150175587-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | DHPS, THPO, CYP11B1 | NAAA 4749/4885IDH1 320/4885FAAH 3848/4885 |
| US-20040053910-A1 | Administering epothilones or desoxyepothilones to a cancer patient as anticarcinogenic agent | GSTA1, GSTO1, GGT1 | NAAA 4489/4885IDH1 1587/4885FAAH 3373/4885 |
| US-20140213618-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | DHPS, THPO, CYP11B1 | NAAA 4749/4885IDH1 320/4885FAAH 3848/4885 |
| US-20050143429-A1 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | DHPS, THPO, EPOR | NAAA 4640/4885IDH1 316/4885FAAH 3870/4885 |
| US-20070032534-A1 | 12,13-desoxyepothilones, used as anticarcinogenic agents | GSTA1, GSTO1, GSTA2 | NAAA 3552/4885IDH1 2768/4885FAAH 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.